Allogene Therapeutics Announces Oral Presentation of Phase
Long-Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrates Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to...
Source: globenewswire.com
Stay updated with breaking news from Includes Additional Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Long-Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrates Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to...
10.06.2023 - Long-Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrates Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous TherapiesPresentation Recaps 12 Patients Treated with Phase 2 Dose ... Seite 1
FinancialContent fully hosted finance channel